135 related articles for article (PubMed ID: 30662078)
1. Performance of urinary survivin as a non-invasive molecular marker of bladdercarcinoma in a schistosomiasis endemic area.
Muhammad AS; Mungadi IA; Ndodu ED; Kalayi GD
Ghana Med J; 2018 Jun; 52(2):74-78. PubMed ID: 30662078
[TBL] [Abstract][Full Text] [Related]
2. The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine.
Eissa S; Badr S; Elhamid SA; Helmy AS; Nour M; Esmat M
Dis Markers; 2013; 34(1):57-62. PubMed ID: 22960341
[TBL] [Abstract][Full Text] [Related]
3. Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer.
Davies B; Chen J; Modugno F; Weissfeld J; Landsittel D; Dhir R; Nelson J; Getzenberg RH
J Urol; 2005 Nov; 174(5):1767-70. PubMed ID: 16217280
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer.
Eissa S; Shabayek MI; Ismail MF; El-Allawy RM; Hamdy MA
IUBMB Life; 2010 May; 62(5):394-9. PubMed ID: 20408180
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of hTERT, KRT7, and survivin in urine for noninvasive detection of bladder cancer using real-time PCR.
Yahyazadeh R; Bashash D; Ghaffari P; Kord S; Safaroghli-Azar A; Ghaffari SH
BMC Urol; 2021 Apr; 21(1):64. PubMed ID: 33874920
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic efficacy of urinary survivin and hyaluronidase mRNA as urine markers in patients with bladder cancer.
Eissa S; Badr S; Barakat M; Zaghloul AS; Mohanad M
Clin Lab; 2013; 59(7-8):893-900. PubMed ID: 24133921
[TBL] [Abstract][Full Text] [Related]
7. Value of urinary survivin as a diagnostic marker in bladder cancer.
Abd El-Hakim TF; El-Shafie MK; Abdou AG; Azmy RM; El-Naidany SS; Badr El-Din MO
Anal Quant Cytopathol Histpathol; 2014 Jun; 36(3):121-7. PubMed ID: 25141488
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of urinary HURP mRNA as a marker for detection of bladder cancer: relation to bilharziasis.
Eissa S; Matboli M; Mansour A; Mohamed S; Awad N; Kotb YM
Med Oncol; 2014 Feb; 31(2):804. PubMed ID: 24375315
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic role of survivin in urinary bladder cancer.
Srivastava AK; Singh PK; Srivastava K; Singh D; Dalela D; Rath SK; Goel MM; Brahma Bhatt ML
Asian Pac J Cancer Prev; 2013; 14(1):81-5. PubMed ID: 23534808
[TBL] [Abstract][Full Text] [Related]
10. Urine detection of survivin and diagnosis of bladder cancer.
Smith SD; Wheeler MA; Plescia J; Colberg JW; Weiss RM; Altieri DC
JAMA; 2001 Jan; 285(3):324-8. PubMed ID: 11176843
[TBL] [Abstract][Full Text] [Related]
11. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology.
Odisho AY; Berry AB; Ahmad AE; Cooperberg MR; Carroll PR; Konety BR
Eur Urol; 2013 May; 63(5):936-40. PubMed ID: 22521093
[TBL] [Abstract][Full Text] [Related]
12. THE SIGNIFICANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND SURVIVIN EXPRESSION IN BLADDER CANCER TISSUE AND URINE CYTOLOGY OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER.
Kehinde EO; Al-Maghrebi M; Anim JT; Kapila K; George SS; Al-Juwaiser A; Memon A
East Afr Med J; 2013 Jan; 90(1):19-27. PubMed ID: 26862626
[TBL] [Abstract][Full Text] [Related]
13. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
Eissa S; Swellam M; Shehata H; El-Khouly IM; El-Zayat T; El-Ahmady O
J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
[TBL] [Abstract][Full Text] [Related]
14. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
15. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.
Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT
Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881
[TBL] [Abstract][Full Text] [Related]
16. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
[TBL] [Abstract][Full Text] [Related]
17. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder.
Sumi S; Arai K; Kitahara S; Yoshida KI
Clin Chim Acta; 2000 Jun; 296(1-2):111-20. PubMed ID: 10807975
[TBL] [Abstract][Full Text] [Related]
18. Use of the nuclear matrix protein 22 Bladder Chek testâ„¢ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.
Balci M; Tuncel A; Guzel O; Aslan Y; Sezgin T; Bilgin O; Senel C; Atan A
Int Urol Nephrol; 2015 Mar; 47(3):473-7. PubMed ID: 25649031
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of bladder tumor antigen quantitative test in the diagnosis of bladder carcinoma in a schistosoma endemic area.
Muhammad AS; Mungadi IA; Darlington NN; Kalayi GD
Urol Ann; 2019; 11(2):143-148. PubMed ID: 31040598
[TBL] [Abstract][Full Text] [Related]
20. [Value of fluorescence in situ hybridization of urine exfoliative cells in diagnosis of urinary bladder neoplasms].
Chen N; Gong J; Zeng H; Wei Q; Zhu YC; Chen M; Zhou Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):109-13. PubMed ID: 21355314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
